• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

Nektar Therap(NKTR.US)

Overview
News
Financials
© 2026 Longbridge|Disclaimer

Event Tracking

Dec16
HC Wainwright Raises Nektar Therapeutics Price Target to $135
18:16
Nektar Therapeutics' Drug Rezpegaldesleukin Fails to Meet Main Goal in Mid-Stage Study, Shares Fall
13:59
Nektar Therapeutics Announces Positive Phase 2b Results for Rezpegaldesleukin in Severe Alopecia Areata
12:31
Nov28
Citi initiates coverage of Nektar Therapeutics with a Buy rating and sets a $102 price target
13:02
Nov17
William Blair Maintains Hold Rating on NKTR
23:26
Nov11
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics
12:02

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.79 M, Net Income -35.52 M, EPS -1.8748

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 11.18 M, Net Income -41.59 M, EPS -2.9525

Jun9
Reverse Stock Split(EST)

1-for-15 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
LVRO
1.362
+202.56%
+0.920
BNAI
4.000
+72.41%
+1.670
GPUS
0.2759
+50.27%
+0.092
PRZO
1.220
+49.69%
+0.405
TBMCR
0.3400
+40.15%
+0.097
NTCL
0.4840
+40.09%
+0.139
TXXD
17.969
+39.16%
+5.057
UAVS
1.120
+37.63%
+0.301
DVLT
0.8958
+37.37%
+0.247
CHOW
0.8298
+36.46%
+0.222
View More